A Toronto-based cannabis company specializing in cannabinoid pills has now started distributing its tablets in the maritimes.
On Monday, Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) announced its entry into the Nova Scotia cannabis market.
The company says that the new move is a continuation of its efforts to expand Canntab’s footprint across Canada.
Read more: Poland approves Tilray Medical products for distribution and wholesale
Read more: Jointly releases data showcasing cannabis health benefits
Canntab describes itself as a global pharmaceutical company capable of producing the only Health Canada certified pharmaceutical grade cannabis in orally administered solid tablets (available in multiple-dose and time released combinations). The company says it possesses a Cannabis Research License and Cannabis Standard Processing & Sales for Medical Purposes License.
The supplier completed its first shipment of five milligram and 10 milligram THC InstaCann tablets to the Nova Scotia Liquor Corporation (NSLC) on August 15 with a 300 bottle total of each stock keeping unit (SKU) delivered.
Those products also became available on the NSLC’s online platform that day and will become available for in-person purchases throughout the liquor corporation’s dispensaries as of today, August 22.
“While we have our online ecommerce store open for our medical patients, getting into more retail locations while also being listed with the NSLC’s online platform is another positive move for Canntab,” said Richard Goldstein, Co-Founder and Chief Financial Officer.
Canntab trades under the PILL symbol on the Canadian Securities Exchange, with the ticker symbol CTABF on the OTCQX and with TBF1 on the Frankfurt Stock Exchange.
Photo via Canntab Therapeutics
